Razelle Kurzrock Selected Research

TOR Serine-Threonine Kinases

10/2022	Dermatologic Disease-Directed Targeted Therapy (D3T2): The Application of Biomarker-Based Precision Medicine for the Personalized Treatment of Skin Conditions-Precision Dermatology.
7/2015	The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab.
1/2013	Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1).
9/2011	Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus.
4/2011	Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment.
4/2011	Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures.
8/2010	Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Razelle Kurzrock Research Topics

Disease

442	Neoplasms (Cancer) 05/2024 - 07/2002
30	Neoplasm Metastasis (Metastasis) 03/2021 - 08/2004
28	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2023 - 11/2008
23	Melanoma (Melanoma, Malignant) 01/2023 - 08/2005
23	Fatigue 01/2021 - 02/2004
22	Breast Neoplasms (Breast Cancer) 01/2024 - 06/2007
22	Pancreatic Neoplasms (Pancreatic Cancer) 12/2023 - 11/2004
22	Colorectal Neoplasms (Colorectal Cancer) 01/2023 - 08/2004
19	Thrombocytopenia (Thrombopenia) 01/2020 - 02/2004
17	Lung Neoplasms (Lung Cancer) 05/2024 - 12/2007
17	Ovarian Neoplasms (Ovarian Cancer) 11/2023 - 03/2011
16	Carcinoma (Carcinomatosis) 01/2023 - 03/2008
12	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 08/2023 - 07/2002
12	Castleman Disease (Castleman's Disease) 07/2020 - 09/2007
11	Microsatellite Instability 03/2024 - 01/2017
11	Hematologic Neoplasms (Hematological Malignancy) 11/2023 - 01/2002
11	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 10/2010
11	Hypertension (High Blood Pressure) 03/2020 - 01/2010
10	Nausea 03/2020 - 10/2002
9	Disease Progression 02/2024 - 07/2008
9	Adenocarcinoma 01/2024 - 12/2009
9	Hepatocellular Carcinoma (Hepatoma) 09/2022 - 11/2009
9	Diarrhea 01/2021 - 01/2008
9	Renal Cell Carcinoma (Grawitz Tumor) 10/2020 - 02/2002
9	Exanthema (Rash) 01/2020 - 04/2004
8	Sarcoma (Soft Tissue Sarcoma) 02/2024 - 05/2007
8	Fever (Fevers) 07/2020 - 10/2003
8	Ewing Sarcoma (Sarcoma, Ewing) 07/2020 - 04/2010
8	Infections 07/2020 - 01/2002
8	Neutropenia 03/2020 - 11/2010
8	Leukemia 01/2008 - 07/2002
7	Hodgkin Disease (Hodgkin's Disease) 11/2020 - 02/2004
7	Lymphoma (Lymphomas) 11/2018 - 02/2004
7	Mucositis 04/2014 - 07/2006
6	Circulating Neoplastic Cells 01/2024 - 08/2013
6	Erdheim-Chester Disease 01/2023 - 11/2005
6	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2015 - 06/2008
6	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2014 - 10/2002

Drug/Important Bio-Agent (IBA)

68	Biomarkers (Surrogate Marker)IBA 05/2024 - 09/2008
33	Immune Checkpoint InhibitorsIBA 03/2024 - 01/2017
33	DNA (Deoxyribonucleic Acid)IBA 03/2024 - 06/2009
33	Bevacizumab (Avastin)FDA Link 01/2020 - 01/2010
31	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2023 - 12/2004
30	Circulating Tumor DNAIBA 01/2024 - 11/2016
30	Proteins (Proteins, Gene)FDA Link 01/2024 - 09/2002
24	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 05/2024 - 01/2011
21	RNA (Ribonucleic Acid)IBA 04/2024 - 05/2006
19	Interleukin-6 (Interleukin 6)IBA 07/2020 - 02/2002
17	NivolumabIBA 02/2024 - 01/2016
17	Cell-Free Nucleic AcidsIBA 12/2022 - 01/2016
17	CytokinesIBA 01/2022 - 08/2002
16	Phosphotransferases (Kinase)IBA 03/2023 - 05/2007
16	Monoclonal AntibodiesIBA 11/2022 - 08/2004
15	ErbB Receptors (EGF Receptor)IBA 10/2023 - 07/2008
15	temsirolimus FDA Link 10/2017 - 04/2011
14	CurcuminIBA 04/2016 - 11/2004
13	AntibodiesIBA 05/2024 - 12/2006
13	LigandsIBA 01/2024 - 09/2006
13	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2011 - 08/2002
11	trametinibIBA 03/2024 - 08/2012
11	PlatinumIBA 12/2021 - 04/2011
11	Oxaliplatin (Eloxatin)FDA LinkGeneric 08/2015 - 04/2007
11	tipifarnib (R115777)IBA 04/2011 - 07/2002
10	IpilimumabIBA 02/2024 - 01/2020
10	Tyrosine Kinase InhibitorsIBA 01/2023 - 01/2005
10	Interleukin-8 (Interleukin 8)IBA 08/2013 - 11/2004
10	Farnesyltranstransferase (Farnesyltransferase)IBA 04/2011 - 07/2002
9	Everolimus FDA Link 03/2024 - 11/2013
9	Antineoplastic Agents (Antineoplastics)IBA 03/2021 - 05/2007
9	siltuximabIBA 07/2020 - 08/2010
8	Messenger RNA (mRNA)IBA 02/2024 - 10/2011
8	Trastuzumab (Herceptin)FDA Link 10/2023 - 03/2014
8	EnzymesIBA 01/2023 - 11/2004
8	Cetuximab (Erbitux)FDA Link 01/2022 - 02/2011
8	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2019 - 05/2008
8	Paclitaxel (Taxol)FDA LinkGeneric 01/2019 - 12/2006
8	Sorafenib (BAY 43-9006)FDA Link 02/2015 - 05/2008
8	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 02/2014 - 02/2002
8	NF-kappa B (NF-kB)IBA 12/2009 - 11/2004
7	pembrolizumabIBA 03/2024 - 10/2019
7	CyclinsIBA 01/2023 - 02/2015
7	TOR Serine-Threonine KinasesIBA 10/2022 - 08/2010
7	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021 - 03/2009
7	MTOR InhibitorsIBA 11/2020 - 03/2012
7	Carboplatin (JM8)FDA LinkGeneric 01/2019 - 04/2011
7	Imatinib Mesylate (Gleevec)FDA Link 07/2014 - 08/2006
7	Fluorouracil (Carac)FDA LinkGeneric 02/2013 - 08/2004
6	dabrafenibIBA 03/2024 - 04/2012
6	Sirolimus (Rapamycin)FDA Link 03/2024 - 10/2013
6	human ERBB2 proteinIBA 10/2023 - 07/2014
6	Lipase (Acid Lipase)FDA Link 01/2020 - 12/2010
6	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2020 - 07/2008
6	Interferon-alpha (Interferon Alfa)IBA 01/2020 - 01/2002
5	pazopanib FDA Link 01/2024 - 06/2015

Therapy/Procedure

243	Therapeutics 05/2024 - 01/2002
60	Immunotherapy 04/2024 - 04/2015
45	Drug Therapy (Chemotherapy) 02/2024 - 01/2002
26	Precision Medicine 04/2024 - 09/2011
6	Drug Tapering 01/2019 - 04/2004
5	Molecular Targeted Therapy 04/2024 - 01/2011